Any current/future capex/capital investment/strategic investment?

The transcript does not specifically mention any current or future capital expenditure (capex) or strategic investments in detail. However, Quick Heal Technologies is heavily investing in R&D for new next-generation cybersecurity products, particularly focusing on zero trust, endpoint detection and response (EDR/XDR), and data privacy platforms like HawkkHunt, HawkkProtect, and HawkkScan. The company is scaling its product offerings targeting mid-sized and large enterprises, indicating ongoing strategic investments in product development and market expansion. Quick Heal is also preparing

Future growth expectations in sales/revenue/volumes?

Quick Heal aims to grow revenue from around Rs. 300-350 crores to Rs. 1,000 crores in the next 3 years. The company is targeting a 7% to 10% market share in the mid-sized enterprise segment by FY24, expecting revenues of Rs. 40-50 crores from new products like HawkkHunt, HawkkProtect, and HawkkScan. Enterprise segment revenues are growing sustainably, contributing to 32% of total revenues, with 10 straight quarters of YoY growth. New products focusing on zero trust, EDR/XDR, and data privacy are expected to start generating revenue from the second half of FY24. The company foresees challenges

Future growth expectations in earnings/operating earnings/profits/EPS?

Quick Heal aims to grow revenue from around Rs. 300-350 crores to Rs. 1000 crores in the next 3 years, demonstrating an ambitious growth outlook. New enterprise products like HawkkHunt (EDR/XDR), HawkkProtect, and HawkkScan targeting midsized and large enterprises are expected to start generating revenue from H2 FY24. The company targets capturing 7%-10% market share in India for these new products, translating to Rs. 40-50 crores in additional revenue over the coming years. Enterprise segment revenue grew 27% YoY for 9 months FY23; consumer business is facing short-term degrowth but still mai

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies Limited. However, there is discussion about onboarding new customers for their new products (e.g., HawkkHunt onboarded 5 new customers recently). The management expresses optimism about revenue streams starting from H2 FY24 for new products like HawkkHunt, HawkkProtect, and HawkkScan. The company expects to capture around 7% to 10% market share in these new product categories, translating to potential revenues of Rs. 40-50 crores from these new products in India. There is

IN US

Sale is live|00:00:00left today

Quick Heal Technologies LtdQ4 FY24IT - Software

Quick Heal Technologies Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹177P/E: 196.4Market Cap: ₹1.1K CrSector: IT - Software

Management growth scorecard

Revenue

Category 2

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Quick Heal aims to grow revenue from around Rs. 300-350 crores to Rs. 1,000 crores in the next 3 years.
→The company is targeting a 7% to 10% market share in the mid-sized enterprise segment by FY24, expecting revenues of Rs. 40-50 crores from new products like HawkkHunt, HawkkProtect, and HawkkScan.
→Enterprise segment revenues are growing sustainably, contributing to 32% of total revenues, with 10 straight quarters of YoY growth.
→New products focusing on zero trust, EDR/XDR, and data privacy are expected to start generating revenue from the second half of FY24.
→The company foresees challenges in the short term due to consumer segment degrowth but is investing in R&D and sales to drive long-term growth.
→A gradual transition to enterprise and mid-to-large enterprise markets is planned to scale revenue streams and market presence.

Margin guidance

Category 4

→Quick Heal aims to grow revenue from around Rs. 300-350 crores to Rs. 1000 crores in the next 3 years, demonstrating an ambitious growth outlook.
→New enterprise products like HawkkHunt (EDR/XDR), HawkkProtect, and HawkkScan targeting midsized and large enterprises are expected to start generating revenue from H2 FY24.
→The company targets capturing 7%-10% market share in India for these new products, translating to Rs. 40-50 crores in additional revenue over the coming years.
→Enterprise segment revenue grew 27% YoY for 9 months FY23; consumer business is facing short-term degrowth but still maintains strong gross margins (~95%).
→Focus on trimming costs and improving profitability in near term before scaling revenues.
→Incremental revenues, given the high gross margin, are expected to flow directly to the bottom line, improving operating profits and EPS in the medium term.

3 more insights locked — sign up free to unlock

Fundraise plans

- The transcript does not mention any current or planned fundraising through debt or equity. - The company highlights that it is a zero-debt company, indicating no outstanding debt at present. - The focus is on cost reduction exercises and maintaining a strong balance sheet. - There is no discussion about issuing new equity or raising funds via debt during the call. - Emphasis is placed on investing in R&D and sales through internal resources rather than external fundraising. In summary, Quick Heal Technologies Limited is not contemplating any new fundraising through debt or equity as per the provided transcript.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders for Quick Heal Technologies Limited.
→However, there is discussion about onboarding new customers for their new products (e.g., HawkkHunt onboarded 5 new customers recently).
→The management expresses optimism about revenue streams starting from H2 FY24 for new products like HawkkHunt, HawkkProtect, and HawkkScan.
→The company expects to capture around 7% to 10% market share in these new product categories, translating to potential revenues of Rs. 40-50 crores from these new products in India.
→There is mention of good customer interest and ongoing beta testing for new products, indicating a growing pipeline though no concrete order book figures are disclosed.

Capex plans

Yes

→The transcript does not specifically mention any current or future capital expenditure (capex) or strategic investments in detail.
→However, Quick Heal Technologies is heavily investing in R&D for new next-generation cybersecurity products, particularly focusing on zero trust, endpoint detection and response (EDR/XDR), and data privacy platforms like HawkkHunt, HawkkProtect, and HawkkScan.
→The company is scaling its product offerings targeting mid-sized and large enterprises, indicating ongoing strategic investments in product development and market expansion.
→Quick Heal is also preparing its platform for integration with Managed Security Service Providers (MSSPs) to expand reach to larger enterprises, which implies further investment in partnerships and sales channels.
→No mention of specific capital expenditure projects or amounts is provided in this transcript for FY23 or beyond.

How does Quick Heal Technologies Ltd rank vs peers in IT - Software?

Pro feature

1Quick Heal Technologies Ltd

Rev 2Mar 4

See full IT - Software sector rankings

Want more stocks like Quick Heal Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio